Recent management of extrapyramidal syndrome in antipsychotic use
Abstract
Antipsychotic drugs are crucial for treating mental illnesses but can cause various side effects due to their non-selectivity and high affinity. A study has shown that the prevalence of extrapyramidal side effects among patients with schizophrenia spectrum disorder on antipsychotic medication was 42.6%, with specific side effects including tardive dyskinesia, parkinsonism, and akathisia. These symptoms can significantly impact individuals' quality of life, so effective management is crucial to minimize their impact. Recent advances in the management of EPS include the use of atypical/second-generation antipsychotics and anticholinergic medications. These have been shown to be effective in managing EPS and have a better safety profile than first-generation antipsychotics. Other important strategies for managing EPS include using lower doses of antipsychotics, combination therapy, anticholinergic drugs, and non-pharmacological interventions such as physical therapy, lifestyle modifications, andaddressing potential non-adherence to treatment.
Keywords
References
Ali, T., Sisay, M., Tariku, M., Mekuria, A.N., Desalew, A., 2021. Antipsychotic-Induced Extrapyramidal Side Effects: A Systematic
Review and Meta-Analysis of Observational Studies. PLoS One 16, 6–17.
Cho, H.J., Hallett, M., 2016. Non-Invasive Brain Stimulation for Treatment of Focal Hand Dystonia: Update and Future Direction. J.
Mov. Disord. 9, 55–62.
Cornett, E.M., Novitch, M., Kaye, A.D., Kata, V., Kaye, A.M., 2017. Medication-Induced Tardive Dyskinesia: A Review and Update.
Ochsner J. 17, 162–174.
D’Souza, R.S., Hooten, W.M., 2023. Extrapyramidal Symptoms. Clin. Nurse Spec. 7, 224.
D’Souza, R.S., Mercogliano, C., Ojukwu, E., D’Souza, S., Singles, A., Modi, J., Short, A., Donato, A., 2018. Effects of Prophylactic
Anticholinergic Medications to Decrease Extrapyramidal Side Effects in Patients Taking Acute Antiemetic Drugs: A Systematic Review and Meta-Analysis. Emerg. Med. J. 35, 325–331.
Hope, J., Keks, N.A., 2022. Cariprazine: A New Partial Dopamine Agonist with a Familiar Profile.
Kadakia, A., Brady, B.L., Dembek, C., Williams, G.R., Kent, J.M., 2022. The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Treated with Second Generation Antipsychotics in a Medicaid Population. J. Med. Econ. 25, 87–98.
Kemenkes RI, 2015. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/73/2015 Tentang Pedoman Nasional Pelayanan Kedokteran Jiwa
Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T., McQuade, R.D., 2021. Discovery Research and Development History of the Dopamine D2 Receptor Partial Agonists, Aripiprazole and Brexpiprazole. Neuropsychopharmacol. Reports 41, 134–143.
Koreki, A., Mori, H., Nozaki, S., Koizumi, T., Suzuki, H., Onaya, M., 2021. Risk of Nonalcoholic Fatty Liver Disease in Patients with Schizophrenia Treated with Antipsychotic Drugs: A Cross-sectional Study. J. Clin. Psychopharmacol. 41, 474–477.
Krutika Chokhawala, Lee Stevens, 2023. Antipsychotic Medications. Natl. Libr. Med.
Musselman, M., Faden, J., Citrome, L., 2021. Asenapine: An Atypical Antipsychotic with Atypical Formulations. Ther. Adv. Psychopharmacol. 11, 204512532110352.
Orzelska-Górka, J., Mikulska, J., Wiszniewska, A., Biała, G., 2022. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. Int. J. Mol. Sci. 23.
Pahwa, M., Sleem, A., Elsayed, O.H., Good, M.E., El-Mallakh, R.S., 2021. New Antipsychotic Medications in the Last Decade. Curr. Psychiatry Rep. 23, 1–35.
Pringsheim, T., Barnes, T.R.E., 2018. Antipsychotic Drug-Induced Movement Disorders: A Forgotten Problem? Can. J. Psychiatry 63, 717–718.
Rahman, T., Sahrmann, J.M., Olsen, M.A., Nickel, K.B., Miller, J.P., Ma, C., Grucza, R.A., 2022. Risk of Breast Cancer with Prolactin Elevating Antipsychotic Drugs: An Observational Study of US Women (Ages 18-64 Years). J. Clin. Psychopharmacol. 42, 7–16.
Salem, H., Nagpal, C., Pigott, T., Teixeira, A.L., 2017. Revisiting Antipsychotic-Induced Akathisia: Current Issues and Prospective Challenges. Curr. Neuropharmacol. 15, 789–798.
Sánchez, P., Álamo, C., Almendros, M., Schlueter, M., Tasoulas, A., Martínez, J., 2023. Extrapyramidal Adverse Events and Anticholinergics Use After The Long-Term Treatment of Patients with Schizophrenia with the New Long-Acting Antipsychotic Risperidone ISM®: Results from Matching-Adjusted Indirect Comparisons Versus Once-Monthly Formulatio. Ann. Gen. Psychiatry 22, 1–10.
Shettima, F.B., Sheikh, T.L., Wakil, M.A., Abdulaziz, M., Rabebbe, I.B., O Abdulmalik, J., 2023. Prevalence and Correlates of Extrapyramidal Side Effects Among Patients with Schizophrenia Spectrum Disorders on Typical and Atypical Antipsychotics. Arch. Psychiatry Res. An Int. J. Psychiatry Relat. Sci. 59, 225–240.
Siafis, S., Tzachanis, D., Samara, M., Papazisis, G., 2017. Antipsychotic Drugs: From Receptor-Binding Profiles to Metabolic Side Effects. Curr. Neuropharmacol. 16, 1210–1223.
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J.M., Leucht, S., 2023. Antipsychotic Dose, Dopamine D2 Receptor Occupancy and Extrapyramidal Side-Effects: A Systematic Review and Dose-Response Meta-Analysis. Mol. Psychiatry.
Ślifirski, G., Król, M., Turło, J., 2021. 5-HT Receptors and The Development of New Antidepressants. Int. J. Mol. Sci. 22.
Stroup, T.S., Gray, N., 2018. Management of common adverse effects of antipsychotic medications. World Psychiatry 17, 341–356.
Suski, V., Stacy, M., 2023. Dopamine Agonists. Handb. Park. Dis. Fifth Ed. 414–429.
Termsarasab, P., Frucht, S.J., 2017. Dystonic Storm: A Practical Clinical and Video Review. J. Clin. Mov. Disord. 4, 1–8.
Waln, O., Jankovic, J., 2013. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor and Other Hyperkinetic Movements 3, 1–11.
DOI: 10.24815/jks.v23i2.31434
Refbacks
- There are currently no refbacks.